Industry Research Reports
Home > Reports > Pharma & Healthcare > NAD+ Intravenous Therapy - Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032
NAD+ Intravenous Therapy - Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032
- Description
- Table of Contents
- Table of Figures
- Related Reports
PDF Download
- Description
- Table of Contents
- Table of Figures
- Related Reports
- PDF Download
NAD+ Intravenous Therapy Market Size(US$)
CAGR 2026-2032
8.3%
Market Size,2032
USD 171
Million
Market Snapshot
Market Size in 2026 (Value)
US$ 106 million
Market Forecast in 2032(Value)
US$ 171 million
CAGR
8.3%
Years Considered
2021-2032
Base Year
2026
Forecast Period
2026-2032
Source: Secondary research, interviews with experts, and QYResearch analysis
The global market for NAD+ Intravenous Therapy was estimated to be worth US$ 99 million in 2025 and is projected to reach US$ 171 million, growing at a CAGR of 8.3% from 2026 to 2032.
NAD+ IV Therapy is a wellness therapy that involves the intravenous administration of nicotinamide adenine dinucleotide (NAD+), a coenzyme crucial for cellular energy production and metabolic processes. This therapy is believed to boost energy levels, enhance cognitive function, and promote overall cellular repair by increasing NAD+ levels, which naturally decline with age.
1. Evidence-Driven Transition: NAD⁺ IV Therapy Is Shifting from Concept-Based Anti-Aging to Clinically Validated Intervention
The most fundamental long-term trend for NAD⁺ anti-aging intravenous therapy is its transition from a concept-driven wellness service toward an evidence-based clinical intervention. At present, most claimed benefits of NAD⁺ IV—such as anti-fatigue, cognitive enhancement, metabolic optimization, and longevity—are primarily supported by mechanistic studies, animal models, or small observational trials, rather than large-scale randomized controlled trials (RCTs). As regulatory scrutiny increases and medical institutions demand higher scientific rigor, the industry will be forced to generate robust clinical evidence to validate therapeutic outcomes, define clear clinical indications, and demonstrate measurable improvements in objective biomarkers. Over time, NAD⁺ IV is expected to evolve from a loosely defined “anti-aging treatment” into a medically framed intervention with specific use cases, patient stratification, and standardized clinical endpoints.
2. Regulatory Tightening: NAD⁺ IV Therapy Is Moving from a Gray Market into a Strongly Regulated Medical Framework
Another highly certain trend is the progressive tightening of regulatory oversight, which will push NAD⁺ intravenous therapy out of its current semi-gray commercial zone and into a strictly regulated medical framework. In many markets today, NAD⁺ IV is delivered through medical spas, wellness clinics, or functional medicine centers, often without clearly approved indications, standardized drug registration status, or consistent compliance with pharmaceutical regulations. As governments strengthen control over injectable therapies, compounded drugs, and medical advertising, NAD⁺ IV services will increasingly be required to meet formal regulatory standards related to drug sourcing, sterile preparation, clinical justification, physician supervision, and liability management. This regulatory shift will significantly raise entry barriers and is expected to eliminate a large number of low-compliance providers, while favoring hospital systems, licensed clinics, and medically integrated institutions.
3. Safety and Quality Dominance: Sterility, Endotoxin Control, and Supply Chain Integrity Will Become Core Competitive Factors
Safety and pharmaceutical-grade quality control will become the central competitive axis of the NAD⁺ IV industry as it matures. Intravenous administration inherently carries higher systemic risks than oral supplementation, placing stringent demands on sterile manufacturing, endotoxin control, formulation stability, dosage consistency, and cold-chain logistics. Currently, the market exhibits significant heterogeneity in raw material sourcing, preparation standards, and clinical protocols, creating potential safety vulnerabilities. In the future, sustainable operators will be those capable of implementing GMP-level production systems, batch traceability, sterility validation, adverse-event monitoring, and standardized infusion procedures. As a result, NAD⁺ IV therapy will gradually resemble a pharmaceutical medical service rather than a consumer wellness product, with safety compliance itself becoming a major structural barrier to entry.
4. Product Pathway Differentiation: IV Administration Will Become a High-End Niche While Scalable Alternatives Expand
From a product strategy perspective, NAD⁺ IV therapy is structurally constrained from becoming a mass-market solution due to its high operational costs, time-intensive administration, medical dependency, and variability in patient tolerance. As research and commercialization of NAD⁺ precursors and alternative delivery methods continue to advance, market demand will increasingly shift toward more scalable, standardized, and consumer-friendly pathways. In this context, intravenous NAD⁺ will gradually reposition itself as a premium, specialized intervention within functional medicine, longevity clinics, and rehabilitation medicine, while larger market volumes will be captured by non-IV solutions. Long term, NAD⁺ IV is more likely to remain a precision medical tool for specific high-value scenarios rather than a mainstream anti-aging modality.
5. Business Model Evolution: From One-Time Anti-Aging Services to Longitudinal Medical Management Systems
The commercial model of NAD⁺ IV therapy is expected to evolve from transaction-based “anti-aging packages” toward longitudinal medical management systems centered on patient stratification and data feedback. As consumers become more scientifically informed and regulators restrict exaggerated longevity claims, simple service-selling models will lose sustainability. Instead, leading providers will integrate NAD⁺ IV into broader functional medicine frameworks, supported by baseline diagnostics, biomarker tracking, patient segmentation, and outcome monitoring. In this emerging model, NAD⁺ IV is no longer positioned as a standalone product, but as one component within a personalized health optimization ecosystem, where long-term value is generated through continuous medical engagement, data accumulation, and outcome-based service delivery.
This report provides a comprehensive view of the global market for NAD+ Intravenous Therapy, covering total sales revenue, the market share and ranking of key companies, along with analyses by region & country, by Type, and by Application.
The NAD+ Intravenous Therapy market size, estimations, and forecasts are presented in terms of sales revenue ($ millions), with 2025 as the base year and historical and forecast data from 2021 to 2032. The report combines quantitative and qualitative analysis to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current marketplace, and make informed business decisions regarding NAD+ Intravenous Therapy.
Market Segmentation
By Company
- The Wellness Lab
- Conciergemdla
- Azivmedics
- Reset IV
- Thedripclub
- Toronto Functional Medicine Centre
- Mobileivmedics
- Rocky Mountain Ivmedics
- Premiumhealth
- Effect Doctors
- Nadclinic
- Hydrate IV Bar
- LIVV Natural
- BioReset Medical
- IV Boost UK
Consumption by Region
- North America
- United States
- Canada
- Asia-Pacific
- China
- Japan
- South Korea
- Southeast Asia
- India
- Australia
- Rest of Asia-Pacific
- Europe
- Germany
- France
- U.K.
- Italy
- Netherlands
- Nordic Countries
- Rest of Europe
- Latin America
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
- Rest of MEA
Segment by Type
- NAD+ Mixed Vitamin Injections
- Pure NAD+ Injection
Segment by Application
- Clinic
- Hospital
- Others
Segment by Category
- Single-use Injection Type
- Recurring Injection Type
- Others
Segment by Division
- Low-dose Type
- Medium-dose Type
- High-dose Type
Chapter Outline
Chapter 1: Introduces the scope of the report and the global market size (value). It also summarizes market dynamics and recent developments; identifies key drivers and restraints; outlines challenges and risks for players; reviews relevant industry policies.
Chapter 2: Provides a detailed analysis of the NAD+ Intravenous Therapy companies' competitive landscape—including revenue shares, recent development plans, and mergers and acquisitions (M&A).
Chapter 3: Analyzes market segmentation by Type, presenting the size and growth potential of each segment to help readers identify blue-ocean opportunities.
Chapter 4: Analyzes market segmentation by Application, presenting the size and growth potential of each downstream segment to help readers identify blue-ocean opportunities.
Chapter 5: Presents NAD+ Intravenous Therapy revenue at the regional level. It offers a quantitative assessment of market size and growth potential by region and summarizes market development, future prospects, addressable space, and country-level market size worldwide.
Chapter 6: Presents NAD+ Intravenous Therapy revenue at the country level. It provides segmented data by Type and by Application for each country/region.
Chapter 7: Profiles key players, detailing the main companies' product revenue, gross margin, product portfolios, recent developments, etc.
Chapter 8: Analysis of Value Chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
QYResearch's Strengths
Unlike generic global market reports, this study combines macro-level industry trends with hyper-local operational intelligence, empowering data-driven decisions across the Compound Chocolate value chain, addressing:
Market entry risks/opportunities by region
We identify regional market threats and growth prospects to guide your overseas layout.
Product mix optimization based on local practices
We adjust product portfolios in line with local consumption habits.
Competitor tactics in fragmented vs. consolidated markets
We unpack rivals’ operation strategies for scattered and highly concentrated industries.
Full Research Coverage
We cover competition landscape, full supply chain and quantified market size data, and deliver tailor-made customized surveys to meet your unique business demands.
19 Years Industry Expertise
We own self-owned massive exclusive databases, backed by 19 years of global market research experience across thousands of sectors.
24/7 Fast Report Delivery
Our team operates 24 hours a day, 365 days a year, enabling ultra-fast report turnaround to respond to your research needs efficiently.
Localized Strategic Analysis
We integrate regional risk assessment, localized product optimization and competitor analysis to deliver actionable market strategies.
Market entry risks/opportunities by region
All data is cross-verified from multiple industry sources to deliver thorough, precise analysis that supports reliable corporate strategic decisions.
Market entry risks/opportunities by region
We provide responsive, dedicated after-sales support to resolve all follow-up inquiries about reports, data and industry interpretation.
Table of Contents
1 Market Overview
1.1 NAD+ Intravenous Therapy Product Introduction
1.2 Global NAD+ Intravenous Therapy Market Size Forecast (2021–2032)
1.3 NAD+ Intravenous Therapy Market Trends & Drivers
1.3.1 NAD+ Intravenous Therapy Industry Trends
1.3.2 NAD+ Intravenous Therapy Market Drivers & Opportunities
1.3.3 NAD+ Intravenous Therapy Market Challenges
1.3.4 NAD+ Intravenous Therapy Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global NAD+ Intravenous Therapy Players Revenue Ranking (2025)
2.2 Global NAD+ Intravenous Therapy Revenue by Company (2021–2026)
2.3 Key Companies’ R&D and Operations Footprint and Headquarters
2.4 Key Companies NAD+ Intravenous Therapy Product Offerings
2.5 Key Companies General Availability (GA) Timeline for NAD+ Intravenous Therapy
2.6 NAD+ Intravenous Therapy Market Competitive Analysis
2.6.1 NAD+ Intravenous Therapy Market Concentration Rate (2021–2026)
2.6.2 Top 5 and Top 10 Global Companies by NAD+ Intravenous Therapy Revenue in 2025
2.6.3 Global Companies by Tier (Tier 1, Tier 2, Tier 3), based on NAD+ Intravenous Therapy revenue, 2025
2.7 Mergers & Acquisitions and Expansion
3 Segmentation NAD+ Intravenous Therapy Market Classification
3.1 Introduction by Type
3.1.1 NAD+ Mixed Vitamin Injections
3.1.2 Pure NAD+ Injection
3.1.3 Global NAD+ Intravenous Therapy Sales Value by Type
3.1.3.1 Global NAD+ Intravenous Therapy Sales Value by Type (2021 vs 2025 vs 2032)
3.1.3.2 Global NAD+ Intravenous Therapy Sales Value, by Type (2021–2032)
3.1.3.3 Global NAD+ Intravenous Therapy Sales Value, by Type (%), 2021–2032
3.2 Introduction by Injection
3.2.1 Single-use Injection Type
3.2.2 Recurring Injection Type
3.2.3 Others
3.2.4 Global NAD+ Intravenous Therapy Sales Value by Injection
3.2.4.1 Global NAD+ Intravenous Therapy Sales Value by Injection (2021 vs 2025 vs 2032)
3.2.4.2 Global NAD+ Intravenous Therapy Sales Value, by Injection (2021–2032)
3.2.4.3 Global NAD+ Intravenous Therapy Sales Value, by Injection (%), 2021–2032
3.3 Introduction by Dose
3.3.1 Low-dose Type
3.3.2 Medium-dose Type
3.3.3 High-dose Type
3.3.4 Global NAD+ Intravenous Therapy Sales Value by Dose
3.3.4.1 Global NAD+ Intravenous Therapy Sales Value by Dose (2021 vs 2025 vs 2032)
3.3.4.2 Global NAD+ Intravenous Therapy Sales Value, by Dose (2021–2032)
3.3.4.3 Global NAD+ Intravenous Therapy Sales Value, by Dose (%), 2021–2032
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Clinic
4.1.2 Hospital
4.1.3 Others
4.2 Global NAD+ Intravenous Therapy Sales Value by Application
4.2.1 Global NAD+ Intravenous Therapy Sales Value by Application (2021 vs 2025 vs 2032)
4.2.2 Global NAD+ Intravenous Therapy Sales Value by Application (2021–2032)
4.2.3 Global NAD+ Intravenous Therapy Sales Value by Application (%), 2021–2032
5 Segmentation by Region
5.1 Global NAD+ Intravenous Therapy Sales Value by Region
5.1.1 Global NAD+ Intravenous Therapy Sales Value by Region: 2021 vs 2025 vs 2032
5.1.2 Global NAD+ Intravenous Therapy Sales Value by Region (2021–2026)
5.1.3 Global NAD+ Intravenous Therapy Sales Value by Region (2027–2032)
5.1.4 Global NAD+ Intravenous Therapy Sales Value by Region (%), 2021–2032
5.2 North America
5.2.1 North America NAD+ Intravenous Therapy Sales Value, 2021–2032
5.2.2 North America NAD+ Intravenous Therapy Sales Value by Country (%), 2025 vs 2032
5.3 Europe
5.3.1 Europe NAD+ Intravenous Therapy Sales Value, 2021–2032
5.3.2 Europe NAD+ Intravenous Therapy Sales Value by Country (%), 2025 vs 2032
5.4 Asia Pacific
5.4.1 Asia Pacific NAD+ Intravenous Therapy Sales Value, 2021–2032
5.4.2 Asia Pacific NAD+ Intravenous Therapy Sales Value by Subregion (%), 2025 vs 2032
5.5 South America
5.5.1 South America NAD+ Intravenous Therapy Sales Value, 2021–2032
5.5.2 South America NAD+ Intravenous Therapy Sales Value by Country (%), 2025 vs 2032
5.6 Middle East & Africa
5.6.1 Middle East & Africa NAD+ Intravenous Therapy Sales Value, 2021–2032
5.6.2 Middle East & Africa NAD+ Intravenous Therapy Sales Value by Country (%), 2025 vs 2032
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions NAD+ Intravenous Therapy Sales Value Growth Trends, 2021 vs 2025 vs 2032
6.2 Key Countries/Regions NAD+ Intravenous Therapy Sales Value, 2021–2032
6.3 United States
6.3.1 United States NAD+ Intravenous Therapy Sales Value, 2021–2032
6.3.2 United States NAD+ Intravenous Therapy Sales Value by Type (%), 2025 vs 2032
6.3.3 United States NAD+ Intravenous Therapy Sales Value by Application, 2025 vs 2032
6.4 Europe
6.4.1 Europe NAD+ Intravenous Therapy Sales Value, 2021–2032
6.4.2 Europe NAD+ Intravenous Therapy Sales Value by Type (%), 2025 vs 2032
6.4.3 Europe NAD+ Intravenous Therapy Sales Value by Application, 2025 vs 2032
6.5 China
6.5.1 China NAD+ Intravenous Therapy Sales Value, 2021–2032
6.5.2 China NAD+ Intravenous Therapy Sales Value by Type (%), 2025 vs 2032
6.5.3 China NAD+ Intravenous Therapy Sales Value by Application, 2025 vs 2032
6.6 Japan
6.6.1 Japan NAD+ Intravenous Therapy Sales Value, 2021–2032
6.6.2 Japan NAD+ Intravenous Therapy Sales Value by Type (%), 2025 vs 2032
6.6.3 Japan NAD+ Intravenous Therapy Sales Value by Application, 2025 vs 2032
6.7 South Korea
6.7.1 South Korea NAD+ Intravenous Therapy Sales Value, 2021–2032
6.7.2 South Korea NAD+ Intravenous Therapy Sales Value by Type (%), 2025 vs 2032
6.7.3 South Korea NAD+ Intravenous Therapy Sales Value by Application, 2025 vs 2032
6.8 Southeast Asia
6.8.1 Southeast Asia NAD+ Intravenous Therapy Sales Value, 2021–2032
6.8.2 Southeast Asia NAD+ Intravenous Therapy Sales Value by Type (%), 2025 vs 2032
6.8.3 Southeast Asia NAD+ Intravenous Therapy Sales Value by Application, 2025 vs 2032
6.9 India
6.9.1 India NAD+ Intravenous Therapy Sales Value, 2021–2032
6.9.2 India NAD+ Intravenous Therapy Sales Value by Type (%), 2025 vs 2032
6.9.3 India NAD+ Intravenous Therapy Sales Value by Application, 2025 vs 2032
7 Company Profiles
7.1 The Wellness Lab
7.1.1 The Wellness Lab Profile
7.1.2 The Wellness Lab Main Business
7.1.3 The Wellness Lab NAD+ Intravenous Therapy Products, Services, and Solutions
7.1.4 The Wellness Lab NAD+ Intravenous Therapy Revenue (US$ Million), 2021–2026
7.1.5 The Wellness Lab Recent Developments
7.2 Conciergemdla
7.2.1 Conciergemdla Profile
7.2.2 Conciergemdla Main Business
7.2.3 Conciergemdla NAD+ Intravenous Therapy Products, Services, and Solutions
7.2.4 Conciergemdla NAD+ Intravenous Therapy Revenue (US$ Million), 2021–2026
7.2.5 Conciergemdla Recent Developments
7.3 Azivmedics
7.3.1 Azivmedics Profile
7.3.2 Azivmedics Main Business
7.3.3 Azivmedics NAD+ Intravenous Therapy Products, Services, and Solutions
7.3.4 Azivmedics NAD+ Intravenous Therapy Revenue (US$ Million), 2021–2026
7.3.5 Azivmedics Recent Developments
7.4 Reset IV
7.4.1 Reset IV Profile
7.4.2 Reset IV Main Business
7.4.3 Reset IV NAD+ Intravenous Therapy Products, Services, and Solutions
7.4.4 Reset IV NAD+ Intravenous Therapy Revenue (US$ Million), 2021–2026
7.4.5 Reset IV Recent Developments
7.5 Thedripclub
7.5.1 Thedripclub Profile
7.5.2 Thedripclub Main Business
7.5.3 Thedripclub NAD+ Intravenous Therapy Products, Services, and Solutions
7.5.4 Thedripclub NAD+ Intravenous Therapy Revenue (US$ Million), 2021–2026
7.5.5 Thedripclub Recent Developments
7.6 Toronto Functional Medicine Centre
7.6.1 Toronto Functional Medicine Centre Profile
7.6.2 Toronto Functional Medicine Centre Main Business
7.6.3 Toronto Functional Medicine Centre NAD+ Intravenous Therapy Products, Services, and Solutions
7.6.4 Toronto Functional Medicine Centre NAD+ Intravenous Therapy Revenue (US$ Million), 2021–2026
7.6.5 Toronto Functional Medicine Centre Recent Developments
7.7 Mobileivmedics
7.7.1 Mobileivmedics Profile
7.7.2 Mobileivmedics Main Business
7.7.3 Mobileivmedics NAD+ Intravenous Therapy Products, Services, and Solutions
7.7.4 Mobileivmedics NAD+ Intravenous Therapy Revenue (US$ Million), 2021–2026
7.7.5 Mobileivmedics Recent Developments
7.8 Rocky Mountain Ivmedics
7.8.1 Rocky Mountain Ivmedics Profile
7.8.2 Rocky Mountain Ivmedics Main Business
7.8.3 Rocky Mountain Ivmedics NAD+ Intravenous Therapy Products, Services, and Solutions
7.8.4 Rocky Mountain Ivmedics NAD+ Intravenous Therapy Revenue (US$ Million), 2021–2026
7.8.5 Rocky Mountain Ivmedics Recent Developments
7.9 Premiumhealth
7.9.1 Premiumhealth Profile
7.9.2 Premiumhealth Main Business
7.9.3 Premiumhealth NAD+ Intravenous Therapy Products, Services, and Solutions
7.9.4 Premiumhealth NAD+ Intravenous Therapy Revenue (US$ Million), 2021–2026
7.9.5 Premiumhealth Recent Developments
7.10 Effect Doctors
7.10.1 Effect Doctors Profile
7.10.2 Effect Doctors Main Business
7.10.3 Effect Doctors NAD+ Intravenous Therapy Products, Services, and Solutions
7.10.4 Effect Doctors NAD+ Intravenous Therapy Revenue (US$ Million), 2021–2026
7.10.5 Effect Doctors Recent Developments
7.11 Nadclinic
7.11.1 Nadclinic Profile
7.11.2 Nadclinic Main Business
7.11.3 Nadclinic NAD+ Intravenous Therapy Products, Services, and Solutions
7.11.4 Nadclinic NAD+ Intravenous Therapy Revenue (US$ Million), 2021–2026
7.11.5 Nadclinic Recent Developments
7.12 Hydrate IV Bar
7.12.1 Hydrate IV Bar Profile
7.12.2 Hydrate IV Bar Main Business
7.12.3 Hydrate IV Bar NAD+ Intravenous Therapy Products, Services, and Solutions
7.12.4 Hydrate IV Bar NAD+ Intravenous Therapy Revenue (US$ Million), 2021–2026
7.12.5 Hydrate IV Bar Recent Developments
7.13 LIVV Natural
7.13.1 LIVV Natural Profile
7.13.2 LIVV Natural Main Business
7.13.3 LIVV Natural NAD+ Intravenous Therapy Products, Services, and Solutions
7.13.4 LIVV Natural NAD+ Intravenous Therapy Revenue (US$ Million), 2021–2026
7.13.5 LIVV Natural Recent Developments
7.14 BioReset Medical
7.14.1 BioReset Medical Profile
7.14.2 BioReset Medical Main Business
7.14.3 BioReset Medical NAD+ Intravenous Therapy Products, Services, and Solutions
7.14.4 BioReset Medical NAD+ Intravenous Therapy Revenue (US$ Million), 2021–2026
7.14.5 BioReset Medical Recent Developments
7.15 IV Boost UK
7.15.1 IV Boost UK Profile
7.15.2 IV Boost UK Main Business
7.15.3 IV Boost UK NAD+ Intravenous Therapy Products, Services, and Solutions
7.15.4 IV Boost UK NAD+ Intravenous Therapy Revenue (US$ Million), 2021–2026
7.15.5 IV Boost UK Recent Developments
8 Industry Chain Analysis
8.1 NAD+ Intravenous Therapy Value Chain
8.2 NAD+ Intravenous Therapy Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Key Suppliers of Raw Materials
8.2.3 Cost Structure
8.3 Midstream Analysis
8.4 Downstream (Customer) Analysis
8.5 Sales Model and Sales Channelss
8.5.1 NAD+ Intravenous Therapy Sales Model
8.5.2 Sales Channels
8.5.3 NAD+ Intravenous Therapy Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.1.1 Research Programs/Design
10.1.1.2 Market Size Estimation
10.1.1.3 Market Breakdown and Data Triangulation
10.1.2 Data Source
10.1.2.1 Secondary Sources
10.1.2.2 Primary Sources
10.2 Author Details
10.3 Disclaimer
Table of Figures
List of Tables
Table 1. NAD+ Intravenous Therapy Market Trends
Table 2. NAD+ Intravenous Therapy Market Drivers & Opportunities
Table 3. NAD+ Intravenous Therapy Market Challenges
Table 4. NAD+ Intravenous Therapy Market Restraints
Table 5. Global NAD+ Intravenous Therapy Revenue by Company (US$ Million), 2021–2026
Table 6. Global NAD+ Intravenous Therapy Revenue Market Share by Company (2021–2026)
Table 7. Key Companies’ R&D and Operations Footprint and Headquarters
Table 8. Key Companies NAD+ Intravenous Therapy Product Type
Table 9. Key Companies General Availability (GA) Timeline for NAD+ Intravenous Therapy
Table 10. Global NAD+ Intravenous Therapy Companies Market Concentration Ratio (CR5 and HHI)
Table 11. Global Companies by Tier (Tier 1, Tier 2, Tier 3), based on NAD+ Intravenous Therapy revenue, 2025
Table 12. Mergers & Acquisitions and Expansion Plans
Table 13. Global NAD+ Intravenous Therapy Sales Value by Type: 2021 vs 2025 vs 2032 (US$ Million)
Table 14. Global NAD+ Intravenous Therapy Sales Value by Type (US$ Million), 2021–2026
Table 15. Global NAD+ Intravenous Therapy Sales Value by Type (US$ Million), 2027–2032
Table 16. Global NAD+ Intravenous Therapy Sales Market Share in Value by Type (2021–2026)
Table 17. Global NAD+ Intravenous Therapy Sales Market Share in Value by Type (2027–2032)
Table 18. Global NAD+ Intravenous Therapy Sales Value by Injection: 2021 vs 2025 vs 2032 (US$ Million)
Table 19. Global NAD+ Intravenous Therapy Sales Value by Injection (US$ Million), 2021–2026
Table 20. Global NAD+ Intravenous Therapy Sales Value by Injection (US$ Million), 2027–2032
Table 21. Global NAD+ Intravenous Therapy Sales Market Share in Value by Injection (2021–2026)
Table 22. Global NAD+ Intravenous Therapy Sales Market Share in Value by Injection (2027–2032)
Table 23. Global NAD+ Intravenous Therapy Sales Value by Dose: 2021 vs 2025 vs 2032 (US$ Million)
Table 24. Global NAD+ Intravenous Therapy Sales Value by Dose (US$ Million), 2021–2026
Table 25. Global NAD+ Intravenous Therapy Sales Value by Dose (US$ Million), 2027–2032
Table 26. Global NAD+ Intravenous Therapy Sales Market Share in Value by Dose (2021–2026)
Table 27. Global NAD+ Intravenous Therapy Sales Market Share in Value by Dose (2027–2032)
Table 28. Global NAD+ Intravenous Therapy Sales Value by Application: 2021 vs 2025 vs 2032 (US$ Million)
Table 29. Global NAD+ Intravenous Therapy Sales Value by Application (US$ Million), 2021–2026
Table 30. Global NAD+ Intravenous Therapy Sales Value by Application (US$ Million), 2027–2032
Table 31. Global NAD+ Intravenous Therapy Sales Market Share in Value by Application (2021–2026)
Table 32. Global NAD+ Intravenous Therapy Sales Market Share in Value by Application (2027–2032)
Table 33. Global NAD+ Intravenous Therapy Sales Value by Region, (US$ Million), 2021 vs 2025 vs 2032
Table 34. Global NAD+ Intravenous Therapy Sales Value by Region (US$ Million), 2021–2026
Table 35. Global NAD+ Intravenous Therapy Sales Value by Region (US$ Million), 2027–2032
Table 36. Global NAD+ Intravenous Therapy Sales Value by Region (%), 2021–2026
Table 37. Global NAD+ Intravenous Therapy Sales Value by Region (%), 2027–2032
Table 38. Key Countries/Regions NAD+ Intravenous Therapy Sales Value Growth Trends, (US$ Million): 2021 vs 2025 vs 2032
Table 39. Key Countries/Regions NAD+ Intravenous Therapy Sales Value, (US$ Million), 2021–2026
Table 40. Key Countries/Regions NAD+ Intravenous Therapy Sales Value, (US$ Million), 2027–2032
Table 41. The Wellness Lab Basic Information List
Table 42. The Wellness Lab Description and Business Overview
Table 43. The Wellness Lab NAD+ Intravenous Therapy Products, Services, and Solutions
Table 44. Revenue (US$ Million) in NAD+ Intravenous Therapy Business of The Wellness Lab (2021–2026)
Table 45. The Wellness Lab Recent Developments
Table 46. Conciergemdla Basic Information List
Table 47. Conciergemdla Description and Business Overview
Table 48. Conciergemdla NAD+ Intravenous Therapy Products, Services, and Solutions
Table 49. Revenue (US$ Million) in NAD+ Intravenous Therapy Business of Conciergemdla (2021–2026)
Table 50. Conciergemdla Recent Developments
Table 51. Azivmedics Basic Information List
Table 52. Azivmedics Description and Business Overview
Table 53. Azivmedics NAD+ Intravenous Therapy Products, Services, and Solutions
Table 54. Revenue (US$ Million) in NAD+ Intravenous Therapy Business of Azivmedics (2021–2026)
Table 55. Azivmedics Recent Developments
Table 56. Reset IV Basic Information List
Table 57. Reset IV Description and Business Overview
Table 58. Reset IV NAD+ Intravenous Therapy Products, Services, and Solutions
Table 59. Revenue (US$ Million) in NAD+ Intravenous Therapy Business of Reset IV (2021–2026)
Table 60. Reset IV Recent Developments
Table 61. Thedripclub Basic Information List
Table 62. Thedripclub Description and Business Overview
Table 63. Thedripclub NAD+ Intravenous Therapy Products, Services, and Solutions
Table 64. Revenue (US$ Million) in NAD+ Intravenous Therapy Business of Thedripclub (2021–2026)
Table 65. Thedripclub Recent Developments
Table 66. Toronto Functional Medicine Centre Basic Information List
Table 67. Toronto Functional Medicine Centre Description and Business Overview
Table 68. Toronto Functional Medicine Centre NAD+ Intravenous Therapy Products, Services, and Solutions
Table 69. Revenue (US$ Million) in NAD+ Intravenous Therapy Business of Toronto Functional Medicine Centre (2021–2026)
Table 70. Toronto Functional Medicine Centre Recent Developments
Table 71. Mobileivmedics Basic Information List
Table 72. Mobileivmedics Description and Business Overview
Table 73. Mobileivmedics NAD+ Intravenous Therapy Products, Services, and Solutions
Table 74. Revenue (US$ Million) in NAD+ Intravenous Therapy Business of Mobileivmedics (2021–2026)
Table 75. Mobileivmedics Recent Developments
Table 76. Rocky Mountain Ivmedics Basic Information List
Table 77. Rocky Mountain Ivmedics Description and Business Overview
Table 78. Rocky Mountain Ivmedics NAD+ Intravenous Therapy Products, Services, and Solutions
Table 79. Revenue (US$ Million) in NAD+ Intravenous Therapy Business of Rocky Mountain Ivmedics (2021–2026)
Table 80. Rocky Mountain Ivmedics Recent Developments
Table 81. Premiumhealth Basic Information List
Table 82. Premiumhealth Description and Business Overview
Table 83. Premiumhealth NAD+ Intravenous Therapy Products, Services, and Solutions
Table 84. Revenue (US$ Million) in NAD+ Intravenous Therapy Business of Premiumhealth (2021–2026)
Table 85. Premiumhealth Recent Developments
Table 86. Effect Doctors Basic Information List
Table 87. Effect Doctors Description and Business Overview
Table 88. Effect Doctors NAD+ Intravenous Therapy Products, Services, and Solutions
Table 89. Revenue (US$ Million) in NAD+ Intravenous Therapy Business of Effect Doctors (2021–2026)
Table 90. Effect Doctors Recent Developments
Table 91. Nadclinic Basic Information List
Table 92. Nadclinic Description and Business Overview
Table 93. Nadclinic NAD+ Intravenous Therapy Products, Services, and Solutions
Table 94. Revenue (US$ Million) in NAD+ Intravenous Therapy Business of Nadclinic (2021–2026)
Table 95. Nadclinic Recent Developments
Table 96. Hydrate IV Bar Basic Information List
Table 97. Hydrate IV Bar Description and Business Overview
Table 98. Hydrate IV Bar NAD+ Intravenous Therapy Products, Services, and Solutions
Table 99. Revenue (US$ Million) in NAD+ Intravenous Therapy Business of Hydrate IV Bar (2021–2026)
Table 100. Hydrate IV Bar Recent Developments
Table 101. LIVV Natural Basic Information List
Table 102. LIVV Natural Description and Business Overview
Table 103. LIVV Natural NAD+ Intravenous Therapy Products, Services, and Solutions
Table 104. Revenue (US$ Million) in NAD+ Intravenous Therapy Business of LIVV Natural (2021–2026)
Table 105. LIVV Natural Recent Developments
Table 106. BioReset Medical Basic Information List
Table 107. BioReset Medical Description and Business Overview
Table 108. BioReset Medical NAD+ Intravenous Therapy Products, Services, and Solutions
Table 109. Revenue (US$ Million) in NAD+ Intravenous Therapy Business of BioReset Medical (2021–2026)
Table 110. BioReset Medical Recent Developments
Table 111. IV Boost UK Basic Information List
Table 112. IV Boost UK Description and Business Overview
Table 113. IV Boost UK NAD+ Intravenous Therapy Products, Services, and Solutions
Table 114. Revenue (US$ Million) in NAD+ Intravenous Therapy Business of IV Boost UK (2021–2026)
Table 115. IV Boost UK Recent Developments
Table 116. Revenue (US$ Million) in NAD+ Intravenous Therapy Business of Company 40 (2021–2026)
Table 117. Company 40 Recent Developments
Table 118. Key Raw Materials Lists
Table 119. Key Suppliers of Raw Materials Lists
Table 120. NAD+ Intravenous Therapy Downstream Customers
Table 121. NAD+ Intravenous Therapy Distributors List
Table 122. Research Programs/Design for This Report
Table 123. Key Data Information from Secondary Sources
Table 124. Key Data Information from Primary Sources
List of Figures
Figure 1. NAD+ Intravenous Therapy Product Picture
Figure 2. Global NAD+ Intravenous Therapy Sales Value, 2021 vs 2025 vs 2032 (US$ Million)
Figure 3. Global NAD+ Intravenous Therapy Sales Value (US$ Million), 2021–2032
Figure 4. NAD+ Intravenous Therapy Report Years Considered
Figure 5. Global NAD+ Intravenous Therapy Players Revenue Ranking (US$ Million), 2025
Figure 6. The 5 and 10 Largest Companies in the World: Market Share by NAD+ Intravenous Therapy Revenue in 2025
Figure 7. NAD+ Intravenous Therapy Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2021 vs 2025
Figure 8. NAD+ Mixed Vitamin Injections Picture
Figure 9. Pure NAD+ Injection Picture
Figure 10. Global NAD+ Intravenous Therapy Sales Value by Type (US$ Million), 2021 vs 2025 vs 2032
Figure 11. Global NAD+ Intravenous Therapy Sales Value Market Share by Type, 2025 & 2032
Figure 12. Single-use Injection Type Picture
Figure 13. Recurring Injection Type Picture
Figure 14. Others Picture
Figure 15. Global NAD+ Intravenous Therapy Sales Value by Injection (US$ Million), 2021 vs 2025 vs 2032
Figure 16. Global NAD+ Intravenous Therapy Sales Value Market Share by Injection, 2025 & 2032
Figure 17. Low-dose Type Picture
Figure 18. Medium-dose Type Picture
Figure 19. High-dose Type Picture
Figure 20. Global NAD+ Intravenous Therapy Sales Value by Dose (US$ Million), 2021 vs 2025 vs 2032
Figure 21. Global NAD+ Intravenous Therapy Sales Value Market Share by Dose, 2025 & 2032
Figure 22. Product Picture of Clinic
Figure 23. Product Picture of Hospital
Figure 24. Product Picture of Others
Figure 25. Global NAD+ Intravenous Therapy Sales Value by Application (US$ Million), 2021 vs 2025 vs 2032
Figure 26. Global NAD+ Intravenous Therapy Sales Value Market Share by Application, 2025 & 2032
Figure 27. North America NAD+ Intravenous Therapy Sales Value (US$ Million), 2021–2032
Figure 28. North America NAD+ Intravenous Therapy Sales Value by Country (%), 2025 vs 2032
Figure 29. Europe NAD+ Intravenous Therapy Sales Value (US$ Million), 2021–2032
Figure 30. Europe NAD+ Intravenous Therapy Sales Value by Country (%), 2025 vs 2032
Figure 31. Asia Pacific NAD+ Intravenous Therapy Sales Value (US$ Million), 2021–2032
Figure 32. Asia Pacific NAD+ Intravenous Therapy Sales Value by Subregion (%), 2025 vs 2032
Figure 33. South America NAD+ Intravenous Therapy Sales Value (US$ Million), 2021–2032
Figure 34. South America NAD+ Intravenous Therapy Sales Value by Country (%), 2025 vs 2032
Figure 35. Middle East & Africa NAD+ Intravenous Therapy Sales Value (US$ Million), 2021–2032
Figure 36. Middle East & Africa NAD+ Intravenous Therapy Sales Value by Country (%), 2025 vs 2032
Figure 37. Key Countries/Regions NAD+ Intravenous Therapy Sales Value (%), 2021–2032
Figure 38. United States NAD+ Intravenous Therapy Sales Value (US$ Million), 2021–2032
Figure 39. United States NAD+ Intravenous Therapy Sales Value by Type (%), 2025 vs 2032
Figure 40. United States NAD+ Intravenous Therapy Sales Value by Application (%), 2025 vs 2032
Figure 41. Europe NAD+ Intravenous Therapy Sales Value (US$ Million), 2021–2032
Figure 42. Europe NAD+ Intravenous Therapy Sales Value by Type (%), 2025 vs 2032
Figure 43. Europe NAD+ Intravenous Therapy Sales Value by Application (%), 2025 vs 2032
Figure 44. China NAD+ Intravenous Therapy Sales Value (US$ Million), 2021–2032
Figure 45. China NAD+ Intravenous Therapy Sales Value by Type (%), 2025 vs 2032
Figure 46. China NAD+ Intravenous Therapy Sales Value by Application (%), 2025 vs 2032
Figure 47. Japan NAD+ Intravenous Therapy Sales Value (US$ Million), 2021–2032
Figure 48. Japan NAD+ Intravenous Therapy Sales Value by Type (%), 2025 vs 2032
Figure 49. Japan NAD+ Intravenous Therapy Sales Value by Application (%), 2025 vs 2032
Figure 50. South Korea NAD+ Intravenous Therapy Sales Value (US$ Million), 2021–2032
Figure 51. South Korea NAD+ Intravenous Therapy Sales Value by Type (%), 2025 vs 2032
Figure 52. South Korea NAD+ Intravenous Therapy Sales Value by Application (%), 2025 vs 2032
Figure 53. Southeast Asia NAD+ Intravenous Therapy Sales Value (US$ Million), 2021–2032
Figure 54. Southeast Asia NAD+ Intravenous Therapy Sales Value by Type (%), 2025 vs 2032
Figure 55. Southeast Asia NAD+ Intravenous Therapy Sales Value by Application (%), 2025 vs 2032
Figure 56. India NAD+ Intravenous Therapy Sales Value (US$ Million), 2021–2032
Figure 57. India NAD+ Intravenous Therapy Sales Value by Type (%), 2025 vs 2032
Figure 58. India NAD+ Intravenous Therapy Sales Value by Application (%), 2025 vs 2032
Figure 59. NAD+ Intravenous Therapy Value Chain
Figure 60. NAD+ Intravenous Therapy Cost Structure
Figure 61. Channels of Distribution (Direct Sales, and Distribution)
Figure 62. Bottom-up and Top-down Approaches for This Report
Figure 63. Data Triangulation
Figure 64. Key Executives Interviewed
Related Reports
Global NAD+ Intravenous Therapy Market Insights, Forecast to 2030
The global NAD+ Intravenous Therapy market is projected to grow from US$ 291 million in 2024 to US$ 449 million by 2030, at a Compound Annual Growth Rate (CAGR) of 7.5% during the forecast period.
Published Date: 2024-11-11
Pages: 154
USD 4900.00
(Single User License)
Global and United States NAD+ Intravenous Therapy Market Report & Forecast 2024-2030
The global NAD+ Intravenous Therapy revenue was US$ 281 million in 2023 and is forecast to a readjusted size of US$ 449 million by 2030 with a CAGR of 7.5% during the review period (2024-2030).
Published Date: 2024-11-11
Pages: 131
USD 4350.00
(Single User License)
Global NAD+ Intravenous Therapy Market Research Report 2024
The global NAD+ Intravenous Therapy market was valued at US$ 281 million in 2023 and is anticipated to reach US$ 449 million by 2030, witnessing a CAGR of 7.5% during the forecast period 2024-2030.
Published Date: 2024-11-11
Pages: 100
USD 2900.00
(Single User License)
Global NAD+ Intravenous Therapy Market Research Report 2025
The global market for NAD+ Intravenous Therapy was valued at US$ 291 million in the year 2024 and is projected to reach a revised size of US$ 479 million by 2031, growing at a CAGR of 7.5% during the forecast period.
Published Date: 2025-03-13
Pages: 97
USD 2900.00
(Single User License)
NAD+ Intravenous Therapy - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for NAD+ Intravenous Therapy was estimated to be worth US$ 291 million in 2024 and is forecast to a readjusted size of US$ 479 million by 2031 with a CAGR of 7.5% during the forecast period 2025-2031.
Published Date: 2025-03-13
Pages: 125
USD 3950.00
(Single User License)
Global NAD+ Intravenous Therapy Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031
The global NAD+ Intravenous Therapy market size was US$ 291 million in 2024 and is forecast to a readjusted size of US$ 479 million by 2031 with a CAGR of 7.5% during the forecast period 2025-2031.
Published Date: 2025-03-13
Pages: 105
USD 4250.00
(Single User License)
Global NAD+ Intravenous Therapy Market Outlook, In‑Depth Analysis & Forecast to 2031
The global NAD+ Intravenous Therapy market is projected to grow from US$ 291 million in 2024 to US$ 479 million by 2031, at a CAGR of 7.5% (2025-2031), driven by critical product segments and diverse end‑use applications.
Published Date: 2025-08-05
Pages: 158
USD 4900.00
(Single User License)
Global NAD+ Intravenous Therapy Market Research Report 2026
The global NAD+ Intravenous Therapy market was valued at US$ 99 million in 2025 and is anticipated to reach US$ 171 million by 2032, at a CAGR of 8.3% from 2026 to 2032.
Published Date: 2026-01-31
Pages: 117
USD 2900.00
(Single User License)
Global NAD+ Intravenous Therapy Sales Market Report, Competitive Analysis and Regional Opportunities 2026-2032
The global NAD+ Intravenous Therapy market size was US$ 99 million in 2025 and is forecast to reach a readjusted size of US$ 171 million by 2032 with a CAGR of 8.3% during the forecast period 2026-2032.
Published Date: 2026-03-26
Pages: 94
USD 4250.00
(Single User License)
Global NAD+ Intravenous Therapy Market Outlook, In‑Depth Analysis & Forecast to 2032
The global NAD+ Intravenous Therapy market is projected to grow from US$ 99 million in 2025 to US$ 171 million by 2032, at a CAGR of 8.3% (2026-2032), driven by critical product segments and diverse end‑use applications.
Published Date: 2026-03-26
Pages: 133
USD 4900.00
(Single User License)
Global NAD+ Intravenous Therapy Market Insights, Forecast to 2030
The global NAD+ Intravenous Therapy market is projected to grow from US$ 291 million in 2024 to US$ 449 million by 2030, at a Compound Annual Growth Rate (CAGR) of 7.5% during the forecast period.
Published: 2024-11-11
Pages: 154
USD 4900.00 (Single User License)Global and United States NAD+ Intravenous Therapy Market Report & Forecast 2024-2030
The global NAD+ Intravenous Therapy revenue was US$ 281 million in 2023 and is forecast to a readjusted size of US$ 449 million by 2030 with a CAGR of 7.5% during the review period (2024-2030).
Published: 2024-11-11
Pages: 131
USD 4350.00 (Single User License)Global NAD+ Intravenous Therapy Market Research Report 2024
The global NAD+ Intravenous Therapy market was valued at US$ 281 million in 2023 and is anticipated to reach US$ 449 million by 2030, witnessing a CAGR of 7.5% during the forecast period 2024-2030.
Published: 2024-11-11
Pages: 100
USD 2900.00 (Single User License)Global NAD+ Intravenous Therapy Market Research Report 2025
The global market for NAD+ Intravenous Therapy was valued at US$ 291 million in the year 2024 and is projected to reach a revised size of US$ 479 million by 2031, growing at a CAGR of 7.5% during the forecast period.
Published: 2025-03-13
Pages: 97
USD 2900.00 (Single User License)NAD+ Intravenous Therapy - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for NAD+ Intravenous Therapy was estimated to be worth US$ 291 million in 2024 and is forecast to a readjusted size of US$ 479 million by 2031 with a CAGR of 7.5% during the forecast period 2025-2031.
Published: 2025-03-13
Pages: 125
USD 3950.00 (Single User License)Global NAD+ Intravenous Therapy Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031
The global NAD+ Intravenous Therapy market size was US$ 291 million in 2024 and is forecast to a readjusted size of US$ 479 million by 2031 with a CAGR of 7.5% during the forecast period 2025-2031.
Published: 2025-03-13
Pages: 105
USD 4250.00 (Single User License)Global NAD+ Intravenous Therapy Market Outlook, In‑Depth Analysis & Forecast to 2031
The global NAD+ Intravenous Therapy market is projected to grow from US$ 291 million in 2024 to US$ 479 million by 2031, at a CAGR of 7.5% (2025-2031), driven by critical product segments and diverse end‑use applications.
Published: 2025-08-05
Pages: 158
USD 4900.00 (Single User License)Global NAD+ Intravenous Therapy Market Research Report 2026
The global NAD+ Intravenous Therapy market was valued at US$ 99 million in 2025 and is anticipated to reach US$ 171 million by 2032, at a CAGR of 8.3% from 2026 to 2032.
Published: 2026-01-31
Pages: 117
USD 2900.00 (Single User License)Global NAD+ Intravenous Therapy Sales Market Report, Competitive Analysis and Regional Opportunities 2026-2032
The global NAD+ Intravenous Therapy market size was US$ 99 million in 2025 and is forecast to reach a readjusted size of US$ 171 million by 2032 with a CAGR of 8.3% during the forecast period 2026-2032.
Published: 2026-03-26
Pages: 94
USD 4250.00 (Single User License)Global NAD+ Intravenous Therapy Market Outlook, In‑Depth Analysis & Forecast to 2032
The global NAD+ Intravenous Therapy market is projected to grow from US$ 99 million in 2025 to US$ 171 million by 2032, at a CAGR of 8.3% (2026-2032), driven by critical product segments and diverse end‑use applications.
Published: 2026-03-26
Pages: 133
USD 4900.00 (Single User License)
CHOOSE LICENSE TYPE
USD 3950.00
USD 5925.00
USD 7900.00
Add to Cart
Buy Now
HAVE A QUESTION?
General Email:
REPORT COVERAGE
Market Segmentation
QYResearch's Strengths
TABLE OF CONTENTS
TABLE OF FIGURES
RLEATED REPORTS
Interest In This Report?
Get A Free Sample
Pre-Order Enquiry
OR
Need a Tailored Report?
Customize this report to your needs.
Customize This Report
Fact Checked
Cite this Research